Lysine clonixinate vs naproxen sodium for the acute treatment of migraine: A double-blind, randomized, crossover study

MedGenMed Medscape General Medicine

Volumn 7, Issue 4, 2005, Pages

  Krymchantowski, Abouch Valenty ^a,b   Peixoto, Patrícia ^b   Higashi, Rafael ^a   Silva Jr , Ariovaldo ^b   Schutz, Vivian ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Headache Center of Rio de Janeiro   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CLONIXIN LYSINE; NAPROXEN; PLACEBO; ANALGESIC AGENT; CLONIXIN; DRUG DERIVATIVE; LYSINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG PREFERENCE; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEADACHE; HEARTBURN; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL SOCIETY; MIGRAINE; NAUSEA; PHOTOPHOBIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STOMACH PAIN; VOMITING; ADOLESCENT; BRAZIL; METHODOLOGY; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAZIL; CLONIXIN; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYSINE; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NAPROXEN; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646145508     PISSN: 15310132     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology. 1994;44(suppl4):S24-S39.
2. Rasmussen BK. Epidemiology of headache. Cephalalgia. 1995;15:45-68.
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl7):1-96.
4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia. 1996;16:231-238.
5. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin. 1997;15:1-13.
6. Peroutka SJ. The drug treatment of migraine. In: Hardman JG, Limberd LE, Molinoff PB, Ruddon RW, Giman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. London, United Kingdom: Pergamon; 1996:487-502.
7. Bigal ME, Bordini CA, Specialli JG. Headache treatment in an emergency unit of the city of Ribeirao Preto, Brazil. Arq Neuropsiquiatr. 1999;57:813-819.
8. Krymchantowski AV. Primary Headaches. How to Diagnose and Treat. São Paulo, Brazil: Lemos Editorial; 2002:81-85.
9. Limmroth V, Przywara S. Analgesics. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Vol 17. Basel, Switzerland: Karger; 2000:30-43. Monographs in Clinical Neuroscience.
10. Lipton RB, Stewart WF, Ryan RE, et al. Efficacy and safety of nonprescription combination of acetaminophen, aspirin and caffeine in alleviating headache pain of an acute migraine attack: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55:210-217.
11. Tfelt-Hansen P, Lipton RB. Prioritizing treatment. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:359-362.
12. Dahlof C, Bjorkman R. Diclofenac-K (50 and 100mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993;13:117-123.
13. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia. 1985;5:115-119.
14. Kloster R, Nestvold K, Vilming S. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia. 1992;12:169-171.
15. Pereyra Quintana JR, Levy DE, Brocato N. Comparison of the analgesic effect between lysine clonixinate and a hipno-analgesic. El Dia Medico. 1978;50:6-23.
16. Sierralta F. Lysine clonixinate: interactions with the serotonergic system and naloxone. Program and abstracts of the 9th Latin American Congress of Pharmacology and Therapeutics; 1982; Santiago, Chile. Abstract.
17. Krymchantowski AV, Barbosa JS. Intravenous lysine clonixinate for the treatment of migraine: an open pilot study. Arq Neuropsiquiatr. 1999;57:606-609.
18. Krymchantowski AV, Barbosa JS, Cheim C, Alves LA. Oral lysine clonixinate in the acute treatment of migraine. A double-blind, placebo-controlled study. Arq Neuropsiquiatr. 2001;59:46-49.
19. Mesquita CT, Cacao JC, Villas Boas P, Mattos LF. Lysine clonixinate in the treatment of migraine. RBM. 1996;53:1128-1131.
20. Paredes H, Solis R, Palacios J. The use of intravenous lysine clonixinate for rapid pain relief: an open clinical study. Curr Ther Res. 1996;40:86-91.
21. Insel PA. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon LW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill; 1996:617-657.
22. Johnson ES, Ratcliffe DM, Wilkinson M. Naproxen sodium in the treatment of migraine. Cephalalgia. 1985;5:5-10.
23. Headache Classification Subcommittee of The International Headache Society. The International Classification of Headache Disorders. 2nd ed. Cephalalgia. 2004;24(suppl1):16-149.
24. Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 2000;20:765-786.
25. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Neurology. 1994;44:1587-1592.
26. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan - nonresponders: a survey in 366 migraine patients. Headache. 1996;36:471-475.
27. Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia. 1995;15(suppl15):21-28.
28. Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology. 1996;47:46-51.
29. Tfelt-Hansen P, McEwen J. Nonsteroidal anti-inflammatory drugs in the acute treatment of migraine. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:391-397.
30. Tfelt-Hansen P, Henry P, Mulder LJ, Scheidewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared to oral sumatriptan for migraine. Lancet. 1995;346:923-926.
31. Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache. 1998;38:201-207.
32. Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Exp Rev Neurother. 2005;5:55-61.
33. DSMSG (Diclofenac-K/Sumatriptan Migraine Study Group). Acute treatment of migraine attacks: efficacy and safety of a non-steroidal anti-inflammatory drug, diclofenac-potassium in comparison to oral sumatriptan and placebo. Cephalalgia. 1999;19:232-210.
34. Dib M, Massiou H, Weber M, et al. Efficacy of oral ketoprofen in acute migraine. A double-blind randomized clinical trial. Neurology. 2002;58:1660-1665.
35. OSAM (Oral Sumatriptan and Aspirin Plus Metoclopramide Comparative Study group). A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol. 1992;32:177-184.
36. Lipton RB, Bigal ME, Goadsby PJ. Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review. Cephalalgia. 2004;24:321-332.
37. Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia. 1999;19:186-187.
38. Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 2000;58:428-430.
39. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open pilot study. Cephalalgia. 2002;22:309-312.
40. Smith T, Kudrow D, Stark S, Littlefield D. Targeting multiple mechanisms in migraine treatment: sumatriptan and naproxen sodium is an effective acute migraine therapy. Neurology. 2005;64(suppl1):A402.
41. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache. 1998;38:18-22.
42. Bronm B, Forth W, Ricther E, Sharein E. Effects of acetaminophen and antipyrine on non-inflammatory pain and EEG activity. Pain. 1992;50:213-221.
43. Brune Y, Beck WS, Geislinger G, et al. Aspirin-like drugs may block pain independent of prostaglandin synthesis inhibition. Experientia. 1991;47:257-261.
44. Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs. 1996;52(suppl5):13-23.
45. Kaube H, Hoskin KL, Goadsby PJ. Acetylsalicilic acid inhibits cerebral cortical vasodilatation caused by superior sagittal sinus stimulation in the cat. Eur J Neurol. 1994;1:141-146.
46. Diener HC. Sumatriptan - therapy. In: Diener HC, ed. Drug Treatment of Migraine and Other Headaches. Vol 17. Basel, Switzerland: Karger; 2000:93-109. Monographs in Clinical Neuroscience.